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Abstract
Objective: To study the impact of gender, puberty, and pregnancy on the
expression of POLG disease, one of the most common mitochondrial diseases
known. Methods: Clinical, laboratory, and genetic data were collected retro-
spectively from 155 patients with genetically confirmed POLG disease recruited
from seven European countries. We used the available data to study the impact
of gender, puberty, and pregnancy on disease onset and deterioration. Results:
We found that disease onset early in life was common in both sexes but there
was also a second peak in females around the time of puberty. Further, preg-
nancy had a negative impact with 10 of 14 women (71%) experiencing disease
onset or deterioration during pregnancy. Interpretation: Gender clearly influ-
ences the expression of POLG disease. While onset very early in life was com-
mon in both males and females, puberty in females appeared associated both
with disease onset and increased disease activity. Further, both disease onset
and deterioration, including seizure aggravation and status epilepticus, appeared
to be associated with pregnancy. Thus, whereas disease activity appears maximal
early in life with no subsequent peaks in males, both menarche and pregnancy
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appear associated with disease onset or worsening in females. This suggests that
hormonal changes may be a modulating factor.
Introduction
Mitochondria are essential organelles found in almost all
human cells. The most fundamental function of mito-
chondria is energy production through the process of
oxidative phosphorylation (OXPHOS).1 The respiratory
chain conserves the energy released through intermediary
metabolism and the ATP synthase then uses it to generate
adenosine triphosphate (ATP). Thirteen of the protein
subunits of the OXPHOS system are encoded by mito-
chondrion’s own DNA (mtDNA), while all the remaining
subunits are encoded by the nuclear DNA (nDNA).2
Mitochondrial dysfunction can present at any age with
heterogeneous clinical manifestations and multi-organ
involvement. Nevertheless, mitochondrial disease appears
predominantly to affect tissues with high energy require-
ment, such as the brain, liver, and heart.3–4
Polymerase gamma is the enzyme responsible for repli-
cating and repairing mtDNA. Variants in POLG, the
nuclear gene encoding the catalytic subunit of this enzyme,
are among the most frequent causes of mitochondrial dis-
ease5,6 and cause a variety of clinical phenotypes ranging
from infantile refractory epilepsy and liver failure to juve-
nile and adult-onset epilepsy, myopathy and ataxia, and to
late-onset myopathies with progressive external ophthal-
moplegia.7–10 Epilepsy has a major impact on morbidity
and mortality. Data from a large cohort of individuals with
POLG disease, which was recently published, showed that
epilepsy is significantly associated with poor outcome.11
Mitochondrial diseases have a minimum prevalence of
ca. 1:5000.12 Despite the fact that they are considered the
most common form of inborn error of metabolism, infor-
mation on the impact of gender on these diseases remains
limited and stems mainly from case reports and small case-
series of pregnant women with disorders, such as mito-
chondrial encephalopathy, lactic acidosis, and stroke-like
episodes (MELAS).13–18 Since mutations in POLG are one
of the most common causes of mitochondrial disease, we
wanted to study the impact of gender, puberty, and preg-
nancy on POLG disease with the aim of providing insights
to guide physicians responsible for their management.
Patients and Methods
Study design and population
We conducted a multicenter retrospective study of 155
patients with confirmed pathogenic POLG variants from
12 centers in seven European countries: Norway, Finland,
Sweden, Denmark, The Netherlands, Spain, and the Uni-
ted Kingdom. Detailed demographic, clinical, laboratory,
neuroimaging, and genetic data were obtained. Age of
disease onset was defined as age in months when the
patient first required medical evaluation. The age of onset
of each individual symptom was also identified. End of
follow-up was defined as the patient’s last visit to the hos-
pital or death. Secondary amenorrhea was defined as ces-
sation of menstruation for six consecutive months in a
woman who has previously had regular menstruation. A
detailed description of the clinical, laboratory, and neu-
roimaging data for the whole cohort has been pub-
lished.11 The mean age of thelarche and menarche in the
population of each country participating in the study19–27
is provided in File S1.
Data analysis
In order to study the effect of gender, individuals were
stratified into two groups according to their gender and
further grouped into those with disease onset before
and after onset of puberty (12 years). To study the
effect of pregnancy, females of childbearing age (18–
50 years) were identified and their data were analyzed
separately.
Statistical analysis
Statistical analysis was performed using SPSS (Statistical
Package of Social Sciences), Version 23.0. A two-sided P
value less than 0.05 was considered to be statistically sig-
nificant. For survival analysis, the end-point was time to
death, which was defined as the time in months from the
date of disease onset to the date of death. Univariate sur-
vival analysis was performed using log-rank test (Kaplan–
Meier) to compare differences in survival time between
the subgroups defined above.
Ethical statement
The ethical approval for the study was obtained from the
Regional Committee for Medical and Health Research
Ethics, Western Norway (REK 2014/1783-4). Each partici-
pating country had obtained approval by the local ethical
committee. The study was registered as an audit at Great
Ormond Street Hospital, London, UK (Registration Num-
ber 1675).
2020 ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
POLG, Gender and Pregnancy O. Hikmat et al.
Results
Demography
In the whole study cohort of 155 individuals, age of dis-
ease onset extended from birth to 71 years with median
age of onset 10 years (interquartile range: 19 years). Fifty-
four percent of individuals (n = 83) had disease onset
before the age of 12 years and 46% (n = 72) after this
age. Fifty-one percent (n = 79) were females and 49%
(n = 76) were males.
Major clinical features and gender
differences
Median age of disease onset for males was 5 years, while
for females it was 13 years. Further, the percentage of
males and females presenting prior to or after the age of
12 years differed; before age 12, we found 55% males
(n = 46) and 45% females (n = 37) while after 12 years,
it was 42% (n = 30) and 58% (n = 42). When we ana-
lyzed age of onset for the whole cohort, we found a
bimodal distribution with the first peak early in life (be-
fore the age of 4 years) and the second around 12–
16 years. This bimodal pattern was, however, gender
dependent; it was apparent only in females and was not
seen when we analyzed data only from males (Fig. 1).
Seizures occurred in 69% (n = 107), and acute episodes
of worsening (previously called stroke-like episodes (SLE))
in 37% (n = 52) of individuals. Once again there was a
trend toward a gender difference; a bimodal distribution
with one peak in early life and the second around puberty
was seen in females but not males for both seizures and
SLE (Fig. 1). Further, regardless of the age of disease
onset, status epilepticus was reported in 56% (n = 44/79)
of females and 44% (n = 35/79) of males.
When we looked at other features of POLG disease,
such as ataxia and liver dysfunction, these manifested
more often in males prior to the age of 12 years than
females under 12, while in those with disease onset after
the age of 12 (Fig. 2), it was the reverse. Features such as
peripheral neuropathy, progressive external ophthalmo-
plegia, and ptosis did not show any clear gender differ-
ences. A detailed description of the frequency of each
individual symptom before and after the onset of puberty
is provided in Figure 2 and in File S2.
Secondary amenorrhea was reported in three patients
(one homozygous for p.Trp748Ser, one compound
heterozygous for p.Trp748Ser/p.Gln497His, and one
heterozygous for the dominant p.Tyr955Cys).
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Figure 1. Age of disease onset, onset of seizure, and onset of stroke-like episodes (SLE) in years for the whole study cohort of individuals with
POLG disease and also according to the gender. The figure shows clearly that the age of disease onset, seizure and stroke-like episode (SLE) onset
in females had a bimodal distribution with the first peak in childhood and the second peak around puberty, while males were presented earlier,
and the age of disease onset, seizures and SLE onset had a unimodal distribution with peak of onset during the childhood.
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Impact of pregnancy
Our cohort included 14 women between 18 and 50 years
whom we considered potentially fertile and of childbear-
ing age. Ten of these became pregnant and in all, preg-
nancy had a clear negative impact: five patients presented
with the first signs of their disease in pregnancy and five
with a clinical deterioration. The most critical period for
these women appeared to be the second trimester of
pregnancy (Table 1). Pregnancy was associated with status
epilepticus in six individuals and in three there was evi-
dence of new-onset liver dysfunction (study cases 6, 7,
and 9).
All women who experienced pregnancy-associated dis-
ease onset/worsening were homozygous or compound
heterozygous for the common founder variants p.Ala467Thr
and p.Trp748Ser apart from one who was homozygous
for the p.Gly268Ala variant (Table 1).
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Figure 2. Major clinical features of POLG patients stratified according to gender and puberty onset. SLE, stroke-like episodes, PEO, progressive
external ophthalmoplegia, PNP, peripheral neuropathy.
Table 1. Summary of pregnancy data on POLG patients included in the current study.
Patient no. Variants
Age at
disease
onset
Age at
pregnancy Parity1
Impact of
pregnancy
Gestational age
at disease
debut or
exacerbation
in weeks
Symptoms at
disease
debut/
exacerbation
Survival
status
Age at
death
1 p.Ala467Thr/p.Ala467Thr 18 18 G1P1 Debut 18 Seizure Deceased 54
2 p.Ala467Thr/p.Ala467Thr 23 23 G1P1 Debut 20 Seizure Alive
3 p.Trp748Ser + p.Glu1143Gly2/
p.Trp748Ser + p.Glu1143Gly2
19 33 G1P1 Exacerbation 19 Seizure/SE3 Alive
4 p.Trp748Ser/p.Trp748Ser 15 20 G1P1 Exacerbation 17 Ataxia Alive
5 p.Gly268Ala/p.Gly268Ala 39 39 G1P1 Debut 16 Ataxia Deceased 45
6 p.Trp748Ser/p.Trp748Ser 18 24 G3P2 Exacerbation 18 Seizure/SE3 Deceased 44
7 p.Ala467Thr/p.Ala467Thr 20 20 G1P1 Debut 19 Seizure/SE3 Deceased 39
8 p.Ala467Thr/p.Trp738Ser 14 23 G1P1 Exacerbation 32 Seizure/SE3 Deceased 24
9 p.Ala467Thr/p.Trp738Ser 27 27 G1P1 Debut 17 Ataxia Alive
10 p.Trp748Ser/p.Trp748Ser 18 18 G1P1 Debut 16 Seizure/SE3 Deceased 21
1. G: number of pregnancies, P: number of deliveries after 24 weeks. 2. Polymorphism. 3. SE: status epilepticus.
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Survival and gender differences
There was no significant difference in the overall survival
between males and females. The analysis also showed that
the onset of puberty did not have an impact on survival,
regardless of gender. Interestingly, however, time to death
was clearly shorter in females (median = 77 months) as
compared to males (median = 108 months) regardless of
the age of disease onset.
Discussion
Our study shows that there are differences in the timing
and in the manner that POLG disease manifests between
males and females. Timing of disease onset showed a
bimodal distribution in females with the first peak in
childhood and the second around the time of puberty.
Indeed, approximately half of the females in our cohort
remained asymptomatic until they reached puberty. In
addition, our study shows that pregnancy is a potential
risk for women with POLG disease. Two thirds of women
of childbearing age in our cohort either had disease onset
or experienced disease deterioration during pregnancy. In
contrast, the peak age of onset in males was unimodal
and early in life.
The presenting feature of the disease also showed gen-
der differences. Seizures, SLE, hepatopathy, and ataxia
are major features of POLG disease and their presence
reflects severity of the disease. In our cohort, seizures
and SLE were more common in males prior to the onset
of puberty, while in females, they appeared more com-
mon after the onset of puberty, particularly SLE.
Hepatopathy and ataxia showed similar age-related
trends, albeit less dramatic. In contrast, the frequency of
peripheral neuropathy and PEO showed similar gender
frequencies before and after the age of puberty (Fig. 2,
File S2).
Almost all the women who experienced pregnancy-as-
sociated disease onset/worsening were homozygous or
compound heterozygous for the common founder vari-
ants p.Ala467Thr and p.Trp748Ser; this may reflect ascer-
tainment bias as all of these individuals were recruited
from Norway where those variants are common10. Exacer-
bation of seizures was the major and predominant com-
plication during pregnancy and was associated with status
epilepticus, prolonged hospitalization, and the use of
multiple antiepileptic drugs. Further, two of the individu-
als had disease onset manifesting with ataxia and one had
a clear worsening of ataxia during pregnancy (Table 1).
The finding of secondary amenorrhea in three women
in our cohort confirms previous reports that documented
a link between pathogenic POLG variants and premature
ovarian failure.28,29
Changes in estrogen and progesterone levels clearly
provide a link between menarche and pregnancy. Experi-
mental animal models show that both hormones can alter
neuronal excitability.30,31 Estrogen increases the excitatory
neurotransmitters and may alter the structure of the
synaptic area by increasing the number of dendritic spines
leading to increased cell-to-cell contact. Estrogen may also
contribute to increased brain-derived neurotrophic factor,
which in turn may lead to excess glutamate release and
decreased seizure threshold. Estrogen is therefore consid-
ered to be pro-convulsant.31,32 Progesterone appears to
have a seizure inhibitory effect. Metabolites, such as allo-
pregnanolone, a GABAA receptor-modulating neuros-
teroid, appear to regulate hippocampal neuronal
excitability by exerting a positive allosteric effect on
GABAA receptors.33,34 Studies have, moreover, demon-
strated clustering of seizures in association with cyclic
ovarian hormonal changes also in humans.32,35 The estro-
gen peak occurring with puberty and the menstrual cycle
may also explain the timing of disease onset or deteriora-
tion in females with POLG disease.
Pregnancy is a high-demand metabolic state that
requires optimal energy production to maintain normal
physiological adaptation and fetal growth. Increased levels
of serum lactate during pregnancy, even in healthy
women,36 suggest, therefore, that pregnancy is associated
with metabolic adaptions and potentially a degree of
mitochondrial stress. It is possible to hypothesize that the
increased energy demands affect all tissues, including neu-
rons, and since these are already metabolically compro-
mised, seizure threshold may be reduced. Our study
showed that pregnancy is indeed a high-risk period for
women with POLG disease, particularly the second trime-
ster.
Another potential risk factor is folate deficiency. This
can result in mitochondrial dysfunction by reducing the
expression of genes encoding essential proteins of the
electron transport chain such as cytochrome c oxidase.37–41
The 10 pregnant women included in our study (Table 1)
were Norwegian and would most probably have followed
Norwegian pregnancy guidelines including the recom-
mended daily supplement of 400-microgram folate. This
is, however, only in the first trimester (www.helsenorge.
no). Thus, any potential protective effect given by folate
supplementation in the first trimester may be lost follow-
ing discontinuation and could contribute to the disease
onset in the second trimester.
Given the results of our study, it is pertinent to ask
whether women with POLG disease, especially those
reaching childbearing age, should be counseled on the
potential risk of disease deterioration during pregnancy.
Clearly, proper planning and discussion of issues, such as
sexual health, contraception, and pregnancy, are important.
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Nevertheless, our data suggest that there is a definite risk
associated with pregnancy and that this is the case both
in those with previously recognized disease and in those
who first manifest their disease during pregnancy. Given
this, we feel that women with POLG disease should be
informed of the risks involved and, should they wish to
proceed, we would suggest that they be managed both
prior to and during pregnancy by a multispeciality team
including obstetricians and neurologists/epileptologists.
Identifying those at greatest risk and, thus, those
requiring maximal follow-up is challenging. Individuals
with POLG-related epilepsy show EEG changes particu-
larly involving the occipital regions, and these are present
before the onset of clinically apparent seizures.42–44 While
this is not a particularly robust biomarker, it may be use-
ful in some patients. In the light of the second trimester
worsening, the use of folic acid supplementation beyond
the first trimester may also be a relevant option. Further
studies will be needed to define the risk profile and show
how best to manage fertile women with POLG disease;
however, our data provide a clear indication that preg-
nancy and menarche are times of increased risk for
females with POLG mutations.
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